This strategy focuses on generating antibodies that target specific molecules or ligands that are overexpressed on cancer cells or within the tumor microenvironment. Examples include targeting growth factors and their receptors, such as the epidermal growth factor receptor or the vascular endothelial growth factor receptor, which are often critical for tumor growth and survival. By blocking these key signaling pathways, these antibodies can directly inhibit cancer cell proliferation and survival.
Antibody based Active Targeting System Development Services for Targeted Cancer Therapy
Background Service Workflow Featured Services Highlights Representative Data FAQs Contact
Are you currently facing long drug development cycles, challenges in obtaining highly specific antibodies, or limited efficacy in targeting tumors with an immunosuppressive microenvironment? Our antibody based active targeting system development services for targeted cancer therapy help you accelerate drug discovery, develop highly specific and potent therapeutic agents, and overcome tumor microenvironment challenges through advanced recombinant antibody engineering and innovative conjugation technologies.
Introduction
The core challenge in cancer therapy is the precise elimination of malignant cells with minimal damage to healthy tissue. Antibody-based therapeutics offer a powerful solution, leveraging their exceptional specificity to target tumor-associated antigens. This approach has evolved from early antibodies that directly blocked cellular pathways to sophisticated systems like antibody-drug conjugates (ADCs) and immunocytokines, which deliver potent payloads directly to the disease site. Our services are designed to address this challenge by providing innovative solutions grounded in published scientific literature and proven preclinical models, enabling the development of highly effective targeted therapies.
Fig.1 Targeted drug delivery strategy for liver cancer tissue.1,3
Antibody based Active Targeting System Development Services for Targeted Cancer Therapy at Creative Biolabs
Creative Biolabs offers comprehensive solutions for developing next-generation antibody-based therapeutics that overcome the limitations of conventional treatments. Leveraging years of expertise, we offer a full suite of services dedicated to the design, development, and production of antibodies for highly specific and effective active targeting across a range of therapeutic applications, with a significant focus on cancer.
We assist your project by providing a streamlined, end-to-end service for creating precision-targeted systems, including ADCs, immunocytokines, and bispecific antibodies. Each is engineered with a unique mechanism of action to precisely target and eradicate cancer cells while sparing healthy tissue. Our systems not only promote direct tumor cell killing but also actively remodel the immunosuppressive tumor microenvironment, enabling a more robust and durable immune response.
Service Process
Featured Services
Cellular Targeting based Antibody Production
This approach goes beyond just targeting cancer cells and focuses on engineering antibodies that can engage with specific cell types within the tumor microenvironment (TME). We specialize in developing bispecific antibodies that can simultaneously bind to a tumor cell and an immune effector cell, such as a T-cell or an NK cell. This effectively redirects the immune system to the tumor, leading to a potent and highly localized anti-cancer response, even in immune-suppressive TMEs.
Tissue-Specific Targeting based Antibody Production
This service is designed to create antibodies that bind to antigens or biomarkers uniquely expressed in a specific tissue or organ, often related to the tumor's extracellular matrix (ECM) or vasculature. A prime example is a specific antibody that targets the extra domain B of fibronectin. This particular antigen is highly expressed in the ECM of a wide variety of solid tumors but is largely absent in normal healthy tissues, making it an ideal candidate for targeted delivery of a payload.
pH/Enzyme-Responsive Targeting based Antibody Production
This innovative strategy involves designing antibody-payload conjugates with a built-in "release switch" that is activated by the unique conditions of the tumor microenvironment. The system remains stable and inactive in the systemic circulation, preventing off-target toxicity. The payload is released only when the antibody encounters the low pH or high concentrations of specific enzymes, which are characteristic of the tumor milieu. This ensures precision delivery and maximizes therapeutic efficacy at the disease site.
Key Advantages
- Comprehensive, One-Stop Service: We provide end-to-end solutions, from initial target and strategy planning to final preclinical validation, ensuring a seamless and efficient workflow for your project.
- Advanced Antibody Engineering: Our expertise extends beyond standard monoclonal antibody development to include innovative formats like ADCs, immunocytokines, and bispecific antibodies, allowing us to create the ideal therapeutic for your specific target.
- Proprietary Discovery Platforms: We utilize cutting-edge methodologies, such as our oncofetal antigen-based discovery approach, to generate antibodies with superior specificity and a novel mechanism of action against challenging cancer biomarkers.
- Fully Customizable Solutions: Every project is unique. We offer flexible and customized service packages tailored to your specific target, payload, and development goals, ensuring a personalized approach to your research.
- Stringent Quality Control: Our processes adhere to a well-established quality system. We perform rigorous in vitro and in vivo validation, including binding, stability, and efficacy studies, to guarantee the quality and reliability of your final product.
- Expertise in Overcoming TME Challenges: We specialize in developing immunocytokines and other targeted systems that can successfully penetrate and remodel the immunosuppressive tumor microenvironment, a critical factor for achieving durable therapeutic responses.
- Regulatory Support: Our detailed documentation and comprehensive reports are designed to support your regulatory filings and facilitate a smooth transition from preclinical development to clinical trials.
Typical data
Summary: This study generated monoclonal antibody using human embryonic stem cells (hESCs) as immunogen. The monoclonal antibody binds strongly to hESCs and various ovarian and breast cancer cell lines but weakly or not to normal cells. Its target antigen is identified as Erbb-2, with binding to N-glycan epitopes on Erbb-2 isoforms. The monoclonal antibody internalizes into cancer cells and functions as an ADC, killing cancer cells in vitro and delaying tumor formation in mouse xenograft models. The monoclonal antibody binds different Erbb-2 isoforms without epitope competition. Conclusions: The monoclonal antibody is a potential targeted therapeutic agent for Erbb-2-expressing cancers, offering an alternative to existing therapies.
Fig.2 Assessment of antibody-dependent cell-mediated cytotoxicity activity with reporter genes.2,3
FAQs
How do your antibody-based active targeting systems differ from conventional antibodies?
Conventional antibodies often rely on a single mechanism of action, such as blocking a receptor. Our systems are more advanced, combining the antibody's specificity with a potent payload (e.g., a cytotoxic drug or cytokine) to achieve a more powerful and targeted therapeutic effect. We can also engineer bispecific antibodies to engage multiple targets simultaneously or recruit immune cells directly to the tumor.
My target is expressed on both tumor cells and some healthy tissues. Can you help improve specificity?
Yes. We are experts in developing strategies to improve specificity. We can engineer bispecific antibodies that require the presence of two distinct antigens for activation, or we can target specific epitopes, that are uniquely expressed on cancer cells. This approach minimizes off-target toxicity and enhances the therapeutic index.
What kind of data do I need to provide to start a project?
We require information on your target, such as its sequence, expression profile, and any existing preliminary data you may have. If you have lead antibody candidates, providing their sequences and a description of their properties is also helpful. However, even with limited initial information, our team can work with you to plan a comprehensive discovery and development strategy.
Why Choose Us?
Creative Biolabs is your trusted partner in developing sophisticated antibody-based therapeutics for targeted cancer therapy. Our services, spanning from initial antibody discovery to advanced immunoconjugation, are designed to address the most pressing challenges in oncology. By combining our deep expertise in antibody engineering with innovative strategies for overcoming TME-mediated resistance, we provide a complete solution for your drug discovery needs.
How to Contact Us
To learn more about our antibody based active targeting system development services for targeted cancer therapy or to discuss your specific project, please contact us. Our team of experts is ready to assist you in designing a powerful and effective therapeutic strategy.
References
- Jin, Shijie et al. "Emerging new therapeutic antibody derivatives for cancer treatment." Signal transduction and targeted therapy vol. 7,1 39. 7 Feb. 2022. DOI: https://doi.org/10.1038/s41392-021-00868-x
- Tan, Heng Liang et al. "Conservation of oncofetal antigens on human embryonic stem cells enables discovery of monoclonal antibodies against cancer." Scientific reports vol. 8,1 11608. 2 Aug. 2018. DOI: https://doi.org/10.1038/s41598-018-30070-z
- Distributed under Open Access License CC BY 4.0, without modification.
For research use only. Not intended for any clinical use.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
